RecruitingPhase 3NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Sponsor: Bristol-Myers Squibb
Christiansburg, VA · Norfolk, VA · +36 more sites